High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience

Urology
K L ShulmanN J Vogelzang

Abstract

Treatment of patients with metastatic renal cell carcinoma with high-dose interleukin-2 (IL-2) administered as continuous intravenous (CIV) infusion or as bolus injection results in response rates of 15% to 30%; however, toxicities with these regimens have been severe. A trial in which CIV IL-2 was administered at high doses during days 1 to 5 and at reduced doses during days 10 to 20 reported less toxicity without a decrease in response rates. We treated a series of patients with this regimen and our experience is presented. Seventeen patients with metastatic renal cell carcinoma were treated with IL-2 by CIV at a dose of 18 x 10(6) IU/m2/day for 5 days followed by 4 to 6 days of rest followed by 10 days of CIV IL-2 at a dose of 6 x 10(6) IU/m2/day. Five patients also received CT-1501R, a pentoxifylline derivative. There was 1 partial responder (PR) and there were no complete responses. The patient with the PR had a 14 x 9 cm(2) renal tumor with metastases to lung, pancreas, and liver. A surgical resection induced a CR, but he relapsed 9 months later. Severe toxicities included hyponatremia (serum sodium of less than 123 mmol/L) (n=3), biopsy-proven cardiomyopathy (n=1), creatinine more than 4.5 mg/dL (n=7), and sudden death (...Continue Reading

References

Apr 1, 1992·Journal of Immunotherapy·M GoelB G Redman
Mar 15, 1991·Cancer·J M RichardsN J Vogelzang
Apr 1, 1990·The American Journal of Medicine·L M SchuchterD S Ettinger
Jan 4, 1989·Journal of the National Cancer Institute·R NoraH J Silverman
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham

❮ Previous
Next ❯

Citations

Nov 1, 1996·Journal of the American Academy of Dermatology·A TranvanK M Soltani
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Paul R WalkerWalter D Y Quan
Apr 28, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G BaatenJ Wagstaff
Apr 2, 1998·Journal of Pharmaceutical Sciences·H S Shin, J T Slattery
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marina PartonTim Eisen
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susan E BatesRichard L Piekarz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.